Harbour BioMed Welcomes Vivian Feng as New External Collaboration Leader

In an exciting development for the global biopharmaceutical landscape, Harbour BioMed, a committed player in the discovery and development of innovative antibody therapeutics, has appointed Ms. Vivian Feng as the Senior Vice President and head of External Collaboration. This strategic decision comes at a pivotal time for the company as it aims to enhance its corporate growth through innovative partnerships.

Leadership and Strategy

Vivian Feng will be operating from the company's Shanghai office and will report directly to Mike Patten, the Chief Strategy Officer. Her role is crucial as she will be responsible for steering Harbour BioMed's external collaboration strategy, harmonizing the company’s platform and pipeline with potential partners. The goal is to create long-term growth and increased value for the company’s diverse initiatives in immunology, oncology, and more.

Feng’s efforts will involve supervising business development and licensing initiatives throughout the Harbour BioMed Group. This includes fostering synergy and information exchange among various entities and new ventures while also building the necessary processes and team capabilities to maintain scalability and controlled risk in external collaborations.

A Wealth of Experience

With over 16 years of extensive experience in biopharmaceutical business development, Ms. Feng is well-equipped for this role. Her background includes significant positions at notable companies such as Fosun Pharma, where she most recently led the Business Development Department. During her tenure, she was instrumental in global business development efforts and helped establish a comprehensive group-level business development system that covered aspects such as valuation and risk assessment.

Feng has also excelled in various business development leadership roles at companies like Besins Healthcare Shanghai Limited and Shanghai Tenry Pharmaceutical Group. Her successful track record encompasses international out-licensing ventures, collaborative projects, and evaluations of over 100 products and assets.

Vision for the Future

Dr. Jingsong Wang, Harbour BioMed’s Founder, Chairman, and CEO, expressed enthusiasm for Feng’s arrival, stating, “Vivian’s extensive expertise in global licensing and corporate development will be vital as we continue to expand our innovative pipeline and strengthen our global partnerships.” He emphasized that they look forward to collaborating with her to accelerate growth and fulfill their mission of delivering transformative therapies to patients worldwide.

Responding to her appointment, Ms. Feng remarked, “I am excited to join Harbour BioMed at such a critical stage. The innovative technology platform and differentiated pipeline offer remarkable opportunities for global partnerships.” She reiterated her commitment to building an exceptional external collaboration function that seamlessly connects the company’s scientific capabilities with partners to deliver groundbreaking therapies to patients around the globe.

About Harbour BioMed

Harbour BioMed (HKEX: 02142) is recognized for its commitment to discovering and developing novel antibody therapeutics, operating at the forefront of immunology and oncology. The company is establishing a robust portfolio through a blend of internal R&D capabilities, strategic global collaborations for co-discovery and co-development, and selective acquisitions.

Utilizing its proprietary Harbour Mice® technology platform, the company produces fully human monoclonal antibodies in various formats, further enhancing its offerings with innovative bispecific antibody technologies like HBICE® and HCAb PLUS™. The integration of artificial intelligence via the Hu-mAtrIx™ platform is set to revolutionize the development of next-generation therapies, further solidifying Harbour BioMed's exceptional position in the biopharmaceutical realm.

For additional insights into Harbour BioMed’s initiatives and innovations, visit www.harbourbiomed.com.